APTO Aptose Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: APTO

Price (delayed)

$0.59

Market cap

$54.45M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.61

Enterprise value

$26.73M

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics ...

Highlights
The debt has plunged by 61% YoY and by 32% from the previous quarter
Aptose Biosciences's net income has increased by 2.7% from the previous quarter
The quick ratio has plunged by 53% YoY and by 19% from the previous quarter
Aptose Biosciences's equity has decreased by 47% YoY and by 16% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://aptose.com
Peers: CRBP ADXS IMGN

Key stats

What are the main financial stats of APTO
Market
Shares outstanding
92.29M
Market cap
$54.45M
Enterprise value
$26.73M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.16
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$56.15M
EBITDA
-$55.56M
Free cash flow
-$39.75M
Per share
EPS
-$0.61
Free cash flow per share
-$0.43
Book value per share
$0.51
Revenue per share
$0
TBVPS
$0.62
Balance sheet
Total assets
$57.05M
Total liabilities
$10.23M
Debt
$271,000
Equity
$46.81M
Working capital
$46.34M
Liquidity
Debt to equity
0.01
Current ratio
5.53
Quick ratio
5.41
Net debt/EBITDA
0.5
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-81.1%
Return on equity
-92.9%
Return on invested capital
-225.5%
Return on capital employed
-119.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

APTO stock price

How has the Aptose Biosciences stock price performed over time
Intraday
0.56%
1 week
1.46%
1 month
-9.23%
1 year
-52.03%
YTD
1.72%
QTD
1.72%

Financial performance

How have Aptose Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$56.55M
Net income
-$56.15M
Gross margin
N/A
Net margin
N/A
Aptose Biosciences's net income has increased by 2.7% from the previous quarter
The company's operating income rose by 2.3% QoQ

Growth

What is Aptose Biosciences's growth rate over time

Valuation

What is Aptose Biosciences stock price valuation
P/E
N/A
P/B
1.16
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 3.2% since the previous quarter
The price to book (P/B) is 69% less than the 5-year quarterly average of 3.8 and 23% less than the last 4 quarters average of 1.5
Aptose Biosciences's equity has decreased by 47% YoY and by 16% QoQ

Efficiency

How efficient is Aptose Biosciences business performance
APTO's return on equity has dropped by 73% year-on-year and by 14% since the previous quarter
The return on assets has dropped by 62% year-on-year and by 11% since the previous quarter
Aptose Biosciences's ROIC has increased by 42% YoY and by 7% from the previous quarter

Dividends

What is APTO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for APTO.

Financial health

How did Aptose Biosciences financials performed over time
The quick ratio has plunged by 53% YoY and by 19% from the previous quarter
The company's current ratio has shrunk by 52% YoY and by 20% QoQ
The debt is 99% less than the equity
The debt has plunged by 61% YoY and by 32% from the previous quarter
Aptose Biosciences's equity has decreased by 47% YoY and by 16% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.